WO2023198665A1 - Infusion devices and associated methods - Google Patents
Infusion devices and associated methods Download PDFInfo
- Publication number
- WO2023198665A1 WO2023198665A1 PCT/EP2023/059364 EP2023059364W WO2023198665A1 WO 2023198665 A1 WO2023198665 A1 WO 2023198665A1 EP 2023059364 W EP2023059364 W EP 2023059364W WO 2023198665 A1 WO2023198665 A1 WO 2023198665A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reservoir
- infusion
- infusion device
- therapeutic agent
- heat transfer
- Prior art date
Links
- 238000001802 infusion Methods 0.000 title claims abstract description 126
- 238000000034 method Methods 0.000 title claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 66
- 238000001816 cooling Methods 0.000 claims abstract description 65
- 238000012546 transfer Methods 0.000 claims abstract description 53
- 239000003814 drug Substances 0.000 claims abstract description 52
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 46
- 102000004877 Insulin Human genes 0.000 claims abstract description 33
- 108090001061 Insulin Proteins 0.000 claims abstract description 33
- 229940125396 insulin Drugs 0.000 claims abstract description 33
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 12
- 239000012530 fluid Substances 0.000 claims abstract description 5
- 239000002826 coolant Substances 0.000 claims description 13
- 238000005057 refrigeration Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 6
- 208000005422 Foreign-Body reaction Diseases 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229910000838 Al alloy Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 208000012266 Needlestick injury Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940127095 analogue insulin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 206010062315 Lipohypertrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/44—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for cooling or heating the devices or media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14264—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with means for compensating influence from the environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
Definitions
- the invention relates to infusion devices and associated methods. Particularly, though not exclusively, the invention relates to infusion devices for infusing a therapeutic agent, such as insulin, to patients, such as those living with diabetes.
- a therapeutic agent such as insulin
- the first mode includes syringes and injector pens, which are used to inject a dose of insulin typically three to four times a day (depending on, inter alia, the type of diabetes and blood sugar levels of the patient). While these devices are simple and low cost, delivering each dose of insulin requires a needle stick.
- the second mode uses an infusion pump, sometimes called an insulin pump, which delivers controlled doses of insulin throughout the day.
- An infusion pump can be used to deliver insulin to a patient continuously (basal dose), on demand (bolus dose) or at scheduled intervals. Infusion pumps are more complex and expensive than syringes and pens, though enable improved regulation of blood sugar levels, for example by programmable delivery schedules, and fewer needle sticks.
- the second mode is known as continuous subcutaneous insulin infusion (CSII) therapy.
- CSII continuous subcutaneous insulin infusion
- Infusion pump systems for CSII therapy may be worn by the patient.
- the systems typically comprise a combined infusion pump and reservoir for containing an insulin drug, for example human insulin or analogue insulin, and an insulin infusion set.
- the infusion set may comprise a cannula (for example, a polymeric catheter or metal needle) for insertion subcutaneously into the patient and flexible tubing for fluidly connecting the cannula to the reservoir.
- a cannula for example, a polymeric catheter or metal needle
- the cannula Once the cannula is inserted into the patient, it may remain in place for a period of time, i.e. days, to allow for continuous delivery of the insulin drug.
- the current recommended wear time for insulin infusion sets is two to three days, to avoid problems that may arise relating to the infusion set itself or to the infusion site. However, such problems may still arise within recommended wear times, resulting in early removal of the infusion set and more frequent site rotation across infusion sites (for example buttocks, abdomen
- FBR foreign body reaction
- FBR blood sugar levels
- CGM continuous glucose monitoring
- CGM devices are already achieving 14-day wear times, and are thus currently achieving superior wear times compared to infusion sets.
- unwanted species, whether biological, chemical or physical, present in infusible solutions have undesirable consequences for patients.
- an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat (i.e. heat available from the environment and/or components surrounding the heat transfer surface), the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit.
- ambient heat i.e. heat available from the environment and/or components surrounding the heat transfer surface
- an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir compartment for receiving and at least partially supporting a reservoir within the device; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir compartment to enable transfer of heat from the reservoir compartment to the cooling unit.
- a method of subcutaneous infusion of a therapeutic agent comprising the steps of: providing the infusion device as described above; and cooling, or maintaining a temperature within, the reservoir and/or reservoir compartment prior to delivery of a therapeutic agent from the reservoir to a patient.
- an infusion device for subcutaneous infusion of a therapeutic agent comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface.
- an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface, and wherein the device comprises a refrigeration unit connected to the cooling unit for lowering the temperature of the cooling medium.
- an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface, and wherein the device comprises a refrigeration unit connected to the cooling unit for lowering the temperature of the cooling medium, and wherein the device comprises a temperature sensor for sensing a temperature within the reservoir and a controller for controlling the refrigeration unit in response to the temperature.
- an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the device comprises a reservoir compartment for receiving and at least partially supporting the reservoir within the device.
- an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface, and wherein the device comprises a reservoir compartment for receiving and at least partially supporting the reservoir within the device.
- the cooling unit may comprise a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface.
- the infusion device may comprise a refrigeration unit connected to the cooling unit for lowering the temperature of the cooling medium.
- the infusion device may comprise a temperature sensor for sensing a temperature within the reservoir and a controller for controlling the refrigeration unit in response to the temperature.
- the heat transfer surface is in direct contact with a surface of the reservoir.
- the reservoir and the heat transfer surface may correspond at least partially in shape to facilitate the direct contact therebetween.
- the cooling conduit may be provided as a coil extending around at least a portion of the reservoir.
- the infusion device may comprise a reservoir compartment for receiving and at least partially supporting the reservoir within the device.
- the reservoir compartment may comprise a material having a heat conductivity of at least 80 W/mK.
- the heat transfer surface may be in direct contact with a surface of the reservoir compartment.
- the reservoir compartment and the heat transfer surface may correspond at least partially in shape to facilitate the direct contact therebetween.
- the cooling conduit may be provided as a coil extending around at least a portion of the reservoir compartment.
- the cooling unit may at least partially support the reservoir within the device. Additionally, or alternatively, the cooling unit may at least partially support the reservoir compartment within the device.
- the infusion device may comprise a fluid pump for delivering the therapeutic agent from the reservoir. Additionally, or alternatively, the infusion device may comprise an infusion set comprising tubing and a cannula for insertion into a patient, the tubing for fluidly connecting the reservoir to the cannula to deliver the therapeutic agent to the patient.
- the infusion device may comprise an insulating compartment for insulating the reservoir from sources of heat.
- the therapeutic agent may comprise insulin.
- Devices and methods according to embodiments of the invention may be useful in inhibiting FBR at an infusion site, and thereby may avoid problematic occurrences such as coagulation, occlusion and/or inflammation at the infusion site, and/or encapsulation of the cannula.
- devices and methods according to embodiments of the invention may be useful in inhibiting FBR at the infusion site in diabetic patients receiving CSII therapy, wherein the infusion site is a single infusion site in use for an extended period of time, for example at least four days.
- Devices and methods according to embodiments of the invention may be useful in cooling a therapeutic agent prior to delivery to a patient.
- the therapeutic agent comprises insulin
- cooling the therapeutic agent may preserve and/or stabilise the therapeutic agent, and/or inhibit the formation of unwanted species, for example insulin agglomerates and other particulates, within the therapeutic agent, which may otherwise activate FBR at the infusion site.
- Figure 1 is a schematic perspective view of an infusion device according to an embodiment of the invention.
- Figure 2 is a schematic cutaway view of the infusion device of Figure 1 , shown supported in a casing;
- Figure 3 is a schematic cutaway view of an infusion device according to an embodiment of the invention.
- Embodiments of the invention have particular application for use with infusion pump systems such as an infusion pump for delivery of a therapeutic agent, the infusion pump comprising a fluid pump and a reservoir, and an infusion set having a cannula and tubing for connecting the cannula to the reservoir.
- infusion pump may be an insulin pump for CSII therapy and the therapeutic agent may be an insulin drug, for example human insulin or analogue insulin.
- the invention are intended for delivering insulin to a patient at a single infusion site over an extended period of time.
- an extended period of time is to be understood to mean at least four days. More specifically, an extended period of time may include four to seven days, seven or more days, seven to 10 days, and 10 or more days. An extended period of time may include 14 or more days. Embodiments of the invention may be used in closed loop systems, wherein the extended period of time may be at least equal to the wear time and/or lifetime of a CGM device.
- FIGS 1 and 2 illustrate an infusion device 10 according to an embodiment of the invention.
- the device 10 comprises a reservoir 12 supported within a cooling unit 14.
- the cooling unit comprises a heat transfer surface 16 in contact with an outer surface 18 of the reservoir 12 to enable the cooling unit 14 to cool a therapeutic agent contained within the reservoir 12 (i.e. by transfer of heat from the therapeutic agent to the cooling unit 14 via the reservoir 12).
- the therapeutic agent may be an insulin solution.
- the reservoir 12 has an outlet port 20 for fluidly connecting the reservoir to an infusion site, for example via an infusion set.
- the reservoir 12 may be a substantially cylindrical container suitable for containing the therapeutic agent. However, the reservoir 12 may be any suitable shape, for example cuboid or frustoconical.
- the reservoir 12 may be an insulin cartridge or a vial, such as a proprietary insulin cartridge for an infusion pump system.
- the reservoir 12 may comprise a material having a high heat conductivity property, for example a heat conductivity of at least 80 W/mK. Suitable heat conductivity may be from 80 to 200 W/mK, or even in excess of 200 W/mK. Particularly suitable heat conductivity maybe at least 100 W/mK.
- the reservoir 12 may comprise aluminium, or an aluminium alloy.
- the cooling unit 14 comprises a heat transfer surface 16.
- the heat transfer surface 16 is configured for absorbing ambient heat (i.e. heat available from the immediate surroundings).
- the heat transfer surface 16 may be provided by a conduit 22 for circulating a cooling medium therethrough.
- the conduit 22 may provide a closed-loop for circulating the cooling medium.
- Suitable cooling mediums may include distilled water, an oil or mineral mixture, such as a water-glycol solution, or a refrigerant.
- the conduit 22 is a coil extending around the outer surface of the reservoir 12 to substantially surround the reservoir 12, while leaving an opening 22a for the reservoir 12 to be received within the cooling unit 14.
- the conduit 22 may extend around the outer surface of the reservoir 12 in a serpentine arrangement to substantially surround the reservoir 12.
- the conduit 22 surrounds the outer surface of the reservoir 12 to provide direct, surface-to-surface contact between the reservoir 12 and the heat transfer surface 16.
- the reservoir 12 and the heat transfer surface 16 typically correspond at least partially in shape to facilitate the direct contact therebetween.
- the device 10 may include a component intermediate the reservoir 12 and the heat transfer surface 16, for example a reservoir compartment (not shown).
- the reservoir compartment may receive and at least partially support the reservoir 12 within the device 10.
- the reservoir compartment may support the reservoir 12 in combination with the cooling unit 14.
- the reservoir compartment may allow the reservoir 12 to be releasably secured within the device 10, allowing for the reservoir 12 to be removed and reintroduced, or replaced, to facilitate refilling of the reservoir 12.
- the reservoir 12 may be refilled in situ in certain embodiments.
- the conduit 22 may be a coil extending around an outer surface of the reservoir compartment to substantially surround the compartment. In certain embodiments, the conduit 22 may extend around the outer surface of the reservoir 12 in a serpentine arrangement to substantially surround the reservoir compartment.
- the conduit 22 may surround the outer surface of the reservoir compartment to provide direct, surface-to-surface contact between the reservoir compartment and the heat transfer surface 16.
- the reservoir compartment and the heat transfer surface 16 may typically correspond at least partially in shape to facilitate the direct contact therebetween.
- An inner surface of the reservoir compartment may be configured to provide direct, surface-to-surface contact between the reservoir 12 and the reservoir compartment, and the reservoir 12 and the reservoir compartment may correspond at least partially in shape to facilitate the direct contact therebetween.
- the reservoir compartment may comprise a material having a high heat conductivity property, for example a heat conductivity of at least 80 W/mK. Suitable heat conductivity may be from 80 to 200 W/mK, or even in excess of 200 W/mK. Particularly suitable heat conductivity maybe at least 100 W/mK.
- the reservoir compartment may comprise aluminium, or an aluminium alloy.
- the device 10 may comprise a refrigeration unit 24 connected to the cooling unit 14 for lowering the temperature of the cooling medium.
- the reservoir 12, the cooling unit 14 and/or the refrigeration unit 24 may be individually or collectively supported with a casing 26 (shown in Figure 2) of the device 10.
- the refrigeration unit 24 may include a venting part 28, open to a side of the casing 26, to allow transfer of heat from the cooling unit 14, and consequently from the device 10.
- the device 10 may comprise a controller (not shown).
- the controller may control the refrigeration unit 24 in response to a temperature within the reservoir 12, for example a temperature of the therapeutic fluid.
- the device 10 may include a temperature sensor (not shown) for sensing a temperature within the reservoir 12.
- the temperature sensor may be a thermistor comprising a sensing probe in direct contact with the reservoir 12 and/or or the therapeutic agent when contained within the reservoir 12.
- the controller may be a main controller of an infusion pump system, or an ancillary controller in communication with such a main controller.
- the controller may be configured to enable control by a user, directly or via a main controller, for example to start, stop, or adjust cooling of the therapeutic agent. Control of the cooling may be automatic.
- the device 10 may comprise an insulating compartment (not shown) for insulating the reservoir 12 from sources of heat, such as body heat of the patient.
- the insulating compartment may be configured to at least partially encapsulate at least the reservoir 12 and the cooling unit 14.
- Suitable materials for the insulting compartment include foam materials and reflective foils.
- the cooling unit is configured to facilitate the infusion of insulin at a single infusion site over an extended period of time, for example by inhibiting formulation of unwanted species in insulin solutions such as insulin agglomerates, and thereby increase wear times, for example at least four days, including four to seven days, seven or more days, seven to 10 days, 10 or more days, and 14 or more days. Cooling the insulin prior to injection may also reduce pain at the infusion site.
- FIG 3 illustrates an infusion device 100 according to an embodiment of the invention comprising components of an infusion pump system.
- the device 100 comprises the device 10 described above with reference to Figures 1 and 2 (i.e. including the reservoir 12 and the cooling unit 14).
- the device 100 further comprises an infusion pump 130, which may be an insulin pump, and an infusion set 132.
- the infusion set 132 comprises tubing 134, a cannula 136 for insertion into an infusion site 138 (for example, the sub-dermal fatty tissue of a patient), and an infusion hub 140 for maintaining the cannula in the infusion site 138.
- the device 100 enables delivery of the therapeutic agent from the reservoir 12 to the patient.
Abstract
There is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising a reservoir for containing a therapeutic agent, and a cooling unit comprising a heat transfer surface for absorbing ambient heat. The heat transfer surface is disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit. The infusion device may have application in infusion pump systems such as an infusion pump system for delivery of an insulin drug, the infusion pump system comprising the infusion device, a fluid pump, and an infusion set comprising a cannula and tubing for connecting the cannula to the reservoir, and the infusion device may allow cooling of the therapeutic agent prior to delivery of the therapeutic agent to a patient.
Description
Infusion devices and associated methods
TECHNICAL FIELD
The invention relates to infusion devices and associated methods. Particularly, though not exclusively, the invention relates to infusion devices for infusing a therapeutic agent, such as insulin, to patients, such as those living with diabetes.
BACKGROUND
For patients with diabetes, insulin therapy is often an important part of their treatment, helping to regulate blood sugar levels and store excess glucose for energy. There are two principal modes for delivering insulin. The first mode includes syringes and injector pens, which are used to inject a dose of insulin typically three to four times a day (depending on, inter alia, the type of diabetes and blood sugar levels of the patient). While these devices are simple and low cost, delivering each dose of insulin requires a needle stick. The second mode uses an infusion pump, sometimes called an insulin pump, which delivers controlled doses of insulin throughout the day. An infusion pump can be used to deliver insulin to a patient continuously (basal dose), on demand (bolus dose) or at scheduled intervals. Infusion pumps are more complex and expensive than syringes and pens, though enable improved regulation of blood sugar levels, for example by programmable delivery schedules, and fewer needle sticks. The second mode is known as continuous subcutaneous insulin infusion (CSII) therapy.
Infusion pump systems for CSII therapy may be worn by the patient. The systems typically comprise a combined infusion pump and reservoir for containing an insulin drug, for example human insulin or analogue insulin, and an insulin infusion set. The infusion set may comprise a cannula (for example, a polymeric catheter or metal needle) for insertion subcutaneously into the patient and flexible tubing for fluidly connecting the cannula to the reservoir. Once the cannula is inserted into the patient, it may remain in place for a period of time, i.e. days, to allow for continuous delivery of the insulin drug. The current recommended wear time for insulin infusion sets is two
to three days, to avoid problems that may arise relating to the infusion set itself or to the infusion site. However, such problems may still arise within recommended wear times, resulting in early removal of the infusion set and more frequent site rotation across infusion sites (for example buttocks, abdomen and arms).
While problems relating to the infusion set have been well investigated and addressed in recent years, there remains little understanding and few solutions to address problems relating to the infusion site. Problems relating to the infusion site include pain, bleeding, infection, skin irritation, erythema, lipohypertrophy and lipoatrophy. Problems at the infusion site may lead to the build-up of scar tissue, which consequently lowers insulin sensitivity and increases the risk of hypoglycaemia, as well as having a cosmetic impact on patients. All these problems can deter patients from continuing to use their infusion pumps, resulting in poorer patient outcomes.
It is known that problems at teh infusion site are a consequence of the immune response to the presence of the cannula and the insulin drug in the body. The immune system responds by activating and progressing the foreign body reaction (FBR) - an inflammatory and fibrotic process that occurs upon introducing a foreign material into the body. In FBR, cells of the immune system identify foreign material and attempt to degrade it, or otherwise encapsulate the material by forming a physical barrier to isolate it from the rest of the body. FBR is a problem for increasing wear times of infusion sets in CSII therapy, as the immune system reacts to the inserted cannula and the insulin drug. This limitation prevents realising the full potential of CSII therapy.
The problem presented by FBR is particularly acute in the development of so-called closed-loop systems. In closed-loop systems, am infusion pump system is used in combination with a continuous glucose monitoring (CGM) device, to continually monitor blood sugar levels and adjust the amount of insulin delivered to the patient automatically. CGM devices are already achieving 14-day wear times, and are thus currently achieving superior wear times compared to infusion sets.
Generally, unwanted species, whether biological, chemical or physical, present in infusible solutions have undesirable consequences for patients.
It is an object of embodiments of the invention to provide an improved infusion device that attempts to circumvent FBR, increase wear times of infusion sets, and/or at least mitigate one or more problems associated with known arrangements.
SUMMARY OF THE INVENTION
According to an aspect of the invention, there is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat (i.e. heat available from the environment and/or components surrounding the heat transfer surface), the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit.
According to another aspect of the invention, there is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir compartment for receiving and at least partially supporting a reservoir within the device; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir compartment to enable transfer of heat from the reservoir compartment to the cooling unit.
According to another aspect of the invention there is provided a method of subcutaneous infusion of a therapeutic agent, the method comprising the steps of: providing the infusion device as described above; and cooling, or maintaining a temperature within, the reservoir and/or reservoir compartment prior to delivery of a therapeutic agent from the reservoir to a patient.
According to another aspect of the invention, there is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface.
According to another aspect of the invention, there is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface, and wherein the device comprises a refrigeration unit connected to the cooling unit for lowering the temperature of the cooling medium.
According to another aspect of the invention, there is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface, and wherein the device comprises a refrigeration unit connected to the cooling unit for lowering the temperature of the cooling medium, and wherein the device comprises a temperature sensor for sensing a temperature within the reservoir and a controller for controlling the refrigeration unit in response to the temperature.
According to another aspect of the invention, there is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the device comprises a reservoir compartment for receiving and at least partially supporting the reservoir within the device.
According to another aspect of the invention, there is provided an infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit, wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface, and wherein the device comprises a reservoir compartment for receiving and at least partially supporting the reservoir within the device.
In certain embodiments, the cooling unit may comprise a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface. Additionally, the infusion device may comprise a refrigeration unit connected to the cooling unit for lowering the temperature of the cooling medium. Moreover, the infusion device may comprise a temperature sensor for sensing a temperature within the reservoir and a controller for controlling the refrigeration unit in response to the temperature.
In certain embodiments, the heat transfer surface is in direct contact with a surface of the reservoir. Moreover, the reservoir and the heat transfer surface may correspond at least partially in shape to facilitate the direct contact therebetween. In certain
embodiments, the cooling conduit may be provided as a coil extending around at least a portion of the reservoir.
In certain embodiments, the infusion device may comprise a reservoir compartment for receiving and at least partially supporting the reservoir within the device. The reservoir compartment may comprise a material having a heat conductivity of at least 80 W/mK. The heat transfer surface may be in direct contact with a surface of the reservoir compartment.
In certain embodiments, the reservoir compartment and the heat transfer surface may correspond at least partially in shape to facilitate the direct contact therebetween. Moreover, the cooling conduit may be provided as a coil extending around at least a portion of the reservoir compartment.
In certain embodiments, the cooling unit may at least partially support the reservoir within the device. Additionally, or alternatively, the cooling unit may at least partially support the reservoir compartment within the device.
In certain embodiments, the infusion device may comprise a fluid pump for delivering the therapeutic agent from the reservoir. Additionally, or alternatively, the infusion device may comprise an infusion set comprising tubing and a cannula for insertion into a patient, the tubing for fluidly connecting the reservoir to the cannula to deliver the therapeutic agent to the patient.
In certain embodiments, the infusion device may comprise an insulating compartment for insulating the reservoir from sources of heat. In certain embodiments, the therapeutic agent may comprise insulin.
Devices and methods according to embodiments of the invention may be useful in inhibiting FBR at an infusion site, and thereby may avoid problematic occurrences such
as coagulation, occlusion and/or inflammation at the infusion site, and/or encapsulation of the cannula. In particular, devices and methods according to embodiments of the invention may be useful in inhibiting FBR at the infusion site in diabetic patients receiving CSII therapy, wherein the infusion site is a single infusion site in use for an extended period of time, for example at least four days.
Devices and methods according to embodiments of the invention may be useful in cooling a therapeutic agent prior to delivery to a patient. In particular, devices and methods according to embodiments of the invention may be useful where the therapeutic agent comprises insulin, and cooling the therapeutic agent may preserve and/or stabilise the therapeutic agent, and/or inhibit the formation of unwanted species, for example insulin agglomerates and other particulates, within the therapeutic agent, which may otherwise activate FBR at the infusion site.
BRIEF DESCRIPTION OF THE DRAWINGS
Embodiments of the invention will now be described, by way of example only, with reference to the accompanying figures, in which:
Figure 1 is a schematic perspective view of an infusion device according to an embodiment of the invention;
Figure 2 is a schematic cutaway view of the infusion device of Figure 1 , shown supported in a casing; and
Figure 3 is a schematic cutaway view of an infusion device according to an embodiment of the invention.
DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION
Embodiments of the invention have particular application for use with infusion pump systems such as an infusion pump for delivery of a therapeutic agent, the infusion
pump comprising a fluid pump and a reservoir, and an infusion set having a cannula and tubing for connecting the cannula to the reservoir. However, other applications are contemplated, for example cannula access ports and alternative infusion pump systems such as patch pumps, which have no tubing. In certain embodiments, the infusion pump may be an insulin pump for CSII therapy and the therapeutic agent may be an insulin drug, for example human insulin or analogue insulin. Embodiments of the invention are intended for delivering insulin to a patient at a single infusion site over an extended period of time. Used herein, an extended period of time is to be understood to mean at least four days. More specifically, an extended period of time may include four to seven days, seven or more days, seven to 10 days, and 10 or more days. An extended period of time may include 14 or more days. Embodiments of the invention may be used in closed loop systems, wherein the extended period of time may be at least equal to the wear time and/or lifetime of a CGM device.
Figures 1 and 2 illustrate an infusion device 10 according to an embodiment of the invention. The device 10 comprises a reservoir 12 supported within a cooling unit 14. In the illustrated embodiment, the cooling unit comprises a heat transfer surface 16 in contact with an outer surface 18 of the reservoir 12 to enable the cooling unit 14 to cool a therapeutic agent contained within the reservoir 12 (i.e. by transfer of heat from the therapeutic agent to the cooling unit 14 via the reservoir 12). The therapeutic agent may be an insulin solution. The reservoir 12 has an outlet port 20 for fluidly connecting the reservoir to an infusion site, for example via an infusion set. The reservoir 12 may be a substantially cylindrical container suitable for containing the therapeutic agent. However, the reservoir 12 may be any suitable shape, for example cuboid or frustoconical. In embodiments of the invention, the reservoir 12 may be an insulin cartridge or a vial, such as a proprietary insulin cartridge for an infusion pump system. The reservoir 12 may comprise a material having a high heat conductivity property, for example a heat conductivity of at least 80 W/mK. Suitable heat conductivity may be from 80 to 200 W/mK, or even in excess of 200 W/mK. Particularly suitable heat
conductivity maybe at least 100 W/mK. The reservoir 12 may comprise aluminium, or an aluminium alloy.
As above, the cooling unit 14 comprises a heat transfer surface 16. The heat transfer surface 16 is configured for absorbing ambient heat (i.e. heat available from the immediate surroundings). The heat transfer surface 16 may be provided by a conduit 22 for circulating a cooling medium therethrough. As such, the conduit 22 may provide a closed-loop for circulating the cooling medium. Suitable cooling mediums may include distilled water, an oil or mineral mixture, such as a water-glycol solution, or a refrigerant. In the illustrated embodiment, the conduit 22 is a coil extending around the outer surface of the reservoir 12 to substantially surround the reservoir 12, while leaving an opening 22a for the reservoir 12 to be received within the cooling unit 14. In certain embodiments, the conduit 22 may extend around the outer surface of the reservoir 12 in a serpentine arrangement to substantially surround the reservoir 12. Generally, the conduit 22 surrounds the outer surface of the reservoir 12 to provide direct, surface-to-surface contact between the reservoir 12 and the heat transfer surface 16. As such, the reservoir 12 and the heat transfer surface 16 typically correspond at least partially in shape to facilitate the direct contact therebetween.
In certain embodiments, the device 10 may include a component intermediate the reservoir 12 and the heat transfer surface 16, for example a reservoir compartment (not shown). The reservoir compartment may receive and at least partially support the reservoir 12 within the device 10. The reservoir compartment may support the reservoir 12 in combination with the cooling unit 14. The reservoir compartment may allow the reservoir 12 to be releasably secured within the device 10, allowing for the reservoir 12 to be removed and reintroduced, or replaced, to facilitate refilling of the reservoir 12. Although the reservoir 12 may be refilled in situ in certain embodiments. The conduit 22 may be a coil extending around an outer surface of the reservoir compartment to substantially surround the compartment. In certain embodiments, the conduit 22 may extend around the outer surface of the reservoir 12 in a serpentine
arrangement to substantially surround the reservoir compartment. Generally, the conduit 22 may surround the outer surface of the reservoir compartment to provide direct, surface-to-surface contact between the reservoir compartment and the heat transfer surface 16. As such, the reservoir compartment and the heat transfer surface 16 may typically correspond at least partially in shape to facilitate the direct contact therebetween. An inner surface of the reservoir compartment may be configured to provide direct, surface-to-surface contact between the reservoir 12 and the reservoir compartment, and the reservoir 12 and the reservoir compartment may correspond at least partially in shape to facilitate the direct contact therebetween. The reservoir compartment may comprise a material having a high heat conductivity property, for example a heat conductivity of at least 80 W/mK. Suitable heat conductivity may be from 80 to 200 W/mK, or even in excess of 200 W/mK. Particularly suitable heat conductivity maybe at least 100 W/mK. The reservoir compartment may comprise aluminium, or an aluminium alloy.
The device 10 may comprise a refrigeration unit 24 connected to the cooling unit 14 for lowering the temperature of the cooling medium. The reservoir 12, the cooling unit 14 and/or the refrigeration unit 24 may be individually or collectively supported with a casing 26 (shown in Figure 2) of the device 10. The refrigeration unit 24 may include a venting part 28, open to a side of the casing 26, to allow transfer of heat from the cooling unit 14, and consequently from the device 10. To control the refrigeration unit 24, i.e. control cooling of the therapeutic agent, the device 10 may comprise a controller (not shown). The controller may control the refrigeration unit 24 in response to a temperature within the reservoir 12, for example a temperature of the therapeutic fluid. As such, the device 10 may include a temperature sensor (not shown) for sensing a temperature within the reservoir 12. The temperature sensor may be a thermistor comprising a sensing probe in direct contact with the reservoir 12 and/or or the therapeutic agent when contained within the reservoir 12. The controller may be a main controller of an infusion pump system, or an ancillary controller in communication with such a main controller. The controller may be configured to enable control by a
user, directly or via a main controller, for example to start, stop, or adjust cooling of the therapeutic agent. Control of the cooling may be automatic.
The device 10 may comprise an insulating compartment (not shown) for insulating the reservoir 12 from sources of heat, such as body heat of the patient. The insulating compartment may be configured to at least partially encapsulate at least the reservoir 12 and the cooling unit 14. Suitable materials for the insulting compartment include foam materials and reflective foils.
Generally, the cooling unit is configured to facilitate the infusion of insulin at a single infusion site over an extended period of time, for example by inhibiting formulation of unwanted species in insulin solutions such as insulin agglomerates, and thereby increase wear times, for example at least four days, including four to seven days, seven or more days, seven to 10 days, 10 or more days, and 14 or more days. Cooling the insulin prior to injection may also reduce pain at the infusion site.
Figure 3 illustrates an infusion device 100 according to an embodiment of the invention comprising components of an infusion pump system. The device 100 comprises the device 10 described above with reference to Figures 1 and 2 (i.e. including the reservoir 12 and the cooling unit 14). The device 100 further comprises an infusion pump 130, which may be an insulin pump, and an infusion set 132. The infusion set 132 comprises tubing 134, a cannula 136 for insertion into an infusion site 138 (for example, the sub-dermal fatty tissue of a patient), and an infusion hub 140 for maintaining the cannula in the infusion site 138. The device 100 enables delivery of the therapeutic agent from the reservoir 12 to the patient.
Infusion sets, infusions hubs and infusion pumps suitable for use in embodiments of the invention are known in the art, and examples are disclosed in earlier patent applications, including W02007/092210, WC2010/112521 , US11197949, US5257980 and WO98/9856693, the contents of which are incorporated herein by reference.
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
Claims
1. An infusion device for subcutaneous infusion of a therapeutic agent, the infusion device comprising: a reservoir for containing a therapeutic agent; and a cooling unit comprising a heat transfer surface for absorbing ambient heat, the heat transfer surface being disposed in relation to the reservoir to enable transfer of heat from the reservoir to the cooling unit.
2. An infusion device according to claim 1 , wherein the cooling unit comprises a conduit for circulating a cooling medium therethrough, the cooling conduit comprising the heat transfer surface.
3. An infusion device according to claim 2, wherein the device comprises a refrigeration unit connected to the cooling unit for lowering the temperature of the cooling medium.
4. An infusion device according to claim 3, wherein the device comprises a temperature sensor for sensing a temperature within the reservoir and a controller for controlling the refrigeration unit in response to the temperature.
5. An infusion device according to any preceding claim, wherein the heat transfer surface is in direct contact with a surface of the reservoir.
6. An infusion device according to claim 5, wherein the reservoir and the heat transfer surface correspond at least partially in shape to facilitate the direct contact therebetween.
7. An infusion device according to any of claims 2 to 6, wherein the cooling conduit is provided as a coil extending around at least a portion of the reservoir.
8. An infusion device according to any of claims 1 to 4, wherein the device comprises a reservoir compartment for receiving and at least partially supporting the reservoir within the device.
9. An infusion device according to claim 8, wherein the reservoir compartment comprises a material having a heat conductivity of at least 80 W/mK.
10. An infusion device according to claim 8 or 9, wherein the heat transfer surface is in direct contact with a surface of the reservoir compartment.
11. An infusion device according to claim 10, wherein the reservoir compartment and the heat transfer surface correspond at least partially in shape to facilitate the direct contact therebetween.
12. An infusion device according to any of claims 8 to 11, wherein the cooling conduit is provided as a coil extending around at least a portion of the reservoir compartment.
13. An infusion device according to any preceding claim, wherein the cooling unit at least partially supports the reservoir within the device.
14. An infusion device according to any of claims 8 to 13, wherein the cooling unit at least partially supports the reservoir compartment within the device.
15. An infusion device according to any preceding claim, wherein the device comprises a fluid pump for delivering the therapeutic agent from the reservoir.
16. An infusion device according to any preceding claim, wherein the device comprises an infusion set comprising tubing and a cannula for insertion into a patient,
the tubing fluidly connecting the reservoir to the cannula to deliver the therapeutic agent to the patient.
17. An infusion device according to any preceding claim, wherein the device comprises an insulating compartment for insulating the reservoir from sources of heat.
18. An infusion device according to any preceding claim, wherein the therapeutic agent comprises insulin.
19. A method of subcutaneous infusion of a therapeutic agent, the method comprising the steps of: providing the infusion device according to any preceding claim; cooling, or maintaining a temperature within, the reservoir prior to delivery of a therapeutic agent from the reservoir to a patient.
20. A method according to claim 19, wherein the therapeutic agent comprises insulin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2205305.2 | 2022-04-11 | ||
GBGB2205305.2A GB202205305D0 (en) | 2022-04-11 | 2022-04-11 | Infusion devices and associated methods |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023198665A1 true WO2023198665A1 (en) | 2023-10-19 |
Family
ID=81653267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/059364 WO2023198665A1 (en) | 2022-04-11 | 2023-04-11 | Infusion devices and associated methods |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202205305D0 (en) |
WO (1) | WO2023198665A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4249923A (en) * | 1979-07-10 | 1981-02-10 | Walda Kim L | Cardioplegic fluid refrigeration and delivery system |
US5257980A (en) | 1993-04-05 | 1993-11-02 | Minimed Technologies, Ltd. | Subcutaneous injection set with crimp-free soft cannula |
WO1998056693A1 (en) | 1997-06-13 | 1998-12-17 | Aries Packaging Societe Anonyme | Mechanism for the continuous spacing and transfer of products |
WO2007092210A1 (en) | 2006-02-07 | 2007-08-16 | Icu Medical, Inc. | Infusion set |
US20070244475A1 (en) * | 2006-04-18 | 2007-10-18 | Carson Gary A | Apparatus and method for cooling liquid in intravascular cooling system |
WO2010112521A1 (en) | 2009-03-31 | 2010-10-07 | Unomedical A/S | Inserter device |
US20190009019A1 (en) * | 2017-07-07 | 2019-01-10 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
US11197949B2 (en) | 2017-01-19 | 2021-12-14 | Medtronic Minimed, Inc. | Medication infusion components and systems |
-
2022
- 2022-04-11 GB GBGB2205305.2A patent/GB202205305D0/en not_active Ceased
-
2023
- 2023-04-11 WO PCT/EP2023/059364 patent/WO2023198665A1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4249923A (en) * | 1979-07-10 | 1981-02-10 | Walda Kim L | Cardioplegic fluid refrigeration and delivery system |
US5257980A (en) | 1993-04-05 | 1993-11-02 | Minimed Technologies, Ltd. | Subcutaneous injection set with crimp-free soft cannula |
WO1998056693A1 (en) | 1997-06-13 | 1998-12-17 | Aries Packaging Societe Anonyme | Mechanism for the continuous spacing and transfer of products |
WO2007092210A1 (en) | 2006-02-07 | 2007-08-16 | Icu Medical, Inc. | Infusion set |
US20070244475A1 (en) * | 2006-04-18 | 2007-10-18 | Carson Gary A | Apparatus and method for cooling liquid in intravascular cooling system |
WO2010112521A1 (en) | 2009-03-31 | 2010-10-07 | Unomedical A/S | Inserter device |
US11197949B2 (en) | 2017-01-19 | 2021-12-14 | Medtronic Minimed, Inc. | Medication infusion components and systems |
US20190009019A1 (en) * | 2017-07-07 | 2019-01-10 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
Also Published As
Publication number | Publication date |
---|---|
GB202205305D0 (en) | 2022-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11471592B2 (en) | Extended use medical device | |
US8622991B2 (en) | Method and device for drug delivery | |
KR101509827B1 (en) | Method and device for drug delivery | |
JP6616327B2 (en) | Fluid injection device | |
US9220837B2 (en) | Method and device for drug delivery | |
EP1345640B1 (en) | Therapy management for an implantable medical device | |
EP2349099B1 (en) | Infusion of drugs | |
EP2373256B1 (en) | Stimulation of penis erection | |
WO2002053213A2 (en) | Drug management techniques for an implantable medical device | |
WO2023198665A1 (en) | Infusion devices and associated methods | |
Crinò et al. | Diabetic remission in a cat treated with an implantable pump to deliver insulin | |
KR101032994B1 (en) | Warming chamber for medical treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23720041 Country of ref document: EP Kind code of ref document: A1 |